1	Efficacy and Safety of neoadjuvant stereotactic body radiotherapy plus adebrelimab and	
2	chemotherapy for triple-negative breast cancer: A pilot study	
3		
4	Authors: Guanglei Chen ^{1,2,3†} , Xi Gu ^{1,2,3†} , Xu Zhang ^{1†} , Xiaopeng Yu ^{1†} , Yu Zhang ^{1,4} , Jinqi Xue ^{1,2,3} ,	
5	Ailin Li ¹ , Yi Zhao ¹ , Guijin He ¹ , Meiyue Tang ¹ , Fei Xing ¹ , Jianqiao Yin ¹ , Xiaobo Bian ¹ , Ye Han ¹ ,	
6	Shuo Cao ¹ , Chao Liu ^{1,2,3} , Xiaofan Jiang ^{1,2,3} , Keliang Zhang ⁵ , Yan Xia ⁶ , Huajun Li ⁶ , Nan Niu ^{1,2,3} ,	
7	Caigang Liu ^{1,2,3*}	
8		
9	Author Affiliations:	
10	¹ Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China;	
11	² Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical	
12	University, Shenyang, China;	
13	³ Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province,	
14	Shenyang, China.;	
15	⁴ Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University,	
16	Yantai, China;	
17	⁵ Liaoning Center for Drug Evaluation and Inspection, Shenyang, China;	
18	⁶ Jiangsu Hengrui Pharmaceuticals, Shanghai, China.	
19		
20	Correspondence to	
21	Caigang Liu, Department of Oncology, Shengjing Hospital of China Medical University,	
22	Shenyang 110004, China.	
23	E-mail: liucg@sj-hospital.org	

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26	Background: Emerging data have supported the immunostimulatory role of radiotherapy, which
27	could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but
28	suboptimal efficacy of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed
29	a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT)
30	plus adebrelimab and chemotherapy in TNBC patients.
31	Methods: Treatment-naïve TNBC patients received two cycles of intravenous adebrelimab
32	(20mg/kg, every 3 weeks), and SBRT (24Gy/3f, every other day) started at the second cycle, then
33	followed by six cycles of adebrelimab plus nab-paclitaxel (125 mg/m ² on days 1 and 8) and
34	carboplatin (area under the curve 6 mg/mL per min on day 1) every 3 weeks. The surgery was
35	performed within 3-5 weeks after the end of neoadjuvant therapy. Primary endpoint was
36	pathological complete response (pCR, ypT0/is ypN0). Secondary endpoints included objective
37	response rate (ORR), residual cancer burden (RCB) 0-I and safety.
38	Results: 13 patients were enrolled and received at least one dose of therapy. 10 (76.9%) patients
39	completed SBRT and were included in efficacy analysis. 90% (9/10) of patients achieved pCR, both
40	RCB 0-I and ORR reached 100% with 3 patients achieved complete remission. Adverse events (AEs)
41	of all-grade and grade 3-4 occurred in 92.3% and 53.8%, respectively. 1 (7.7%) patient had
42	treatment-related serious AEs. No radiation-related dermatitis or death occurred.
43	Conclusions: Adding SBRT to adebrelimab and neoadjuvant chemotherapy led to a substantial
44	proportion of pCR with acceptable toxicities, supporting further exploration of this combination in
45	TNBC patients.

- 46 Funding: This research did not receive any specific grant from funding agencies in the public,
- 47 commercial, or not-for-profit sectors.
- 48 Clinical trial number: NCT05132790.
- 49

50 Introduction

51	Triple-negative breast cancer (TNBC), defined as estrogen receptor, progesterone receptor and	
52	human epidermal growth factor receptor 2 (HER2) negative, accounts for approximately 10-20% of	
53	all breast cancers(Costa et al., 2017). Characterized by higher tumor mutation burden and more	
54	intensive tumor-infiltrating lymphocytes (TILs) in tumor microenvironment (TME)(Loi et al., 2019),	
55	TNBC is more sensitive to immune checkpoint inhibitors (ICIs) than any other subtypes(Keenan &	
56	Tolaney, 2020). Nowadays, the combination with pembrolizumab (a PD-1 blockade) and standard	
57	chemotherapy is recommended for TNBC patients with stage II-III according to National	
58	Comprehensive Cancer Network (NCCN) guidelines(Gradishar et al., 2022). However, there is still	
59	around 40% of TNBC patients cannot achieve a pathological complete response (pCR) according	
60	to KEYNOTE-522 (Schmid et al., 2020) and IMpassion031 (Mittendorf et al., 2020) trials, which	
61	calls for more promising strategies.	
62	Radiotherapy (RT) is the most critical locoregional treatment in solid malignancies and	
63	approximately half of patients may receive RT during the entire treatment period (Atun et al., 2015;	

63 approximately half of patients may receive RT during the entire treatment period (Atun et al., 2015; 64 Citrin, 2017). Stereotactic body radiotherapy (SBRT), a novel technique with higher doses of 65 radiation delivery to the tumor lesion in a smaller number of fractions, can shorten treatment 66 dduration and reduce exposure to the surrounding tissues (Chen et al., 2020). SBRT has already 67 been widely applied to advanced breast cancer as salvage treatment targeting to osseous and brain 68 metastasis or other oligometastatic sites (Nicosia et al., 2022; Viani et al., 2021). Preoperative SBRT 69 may be advantageous for downstaging the tumor to enable breast conservation and improving pCR 70 rate (Piras et al., 2023), with multiple trials investigating neoadjuvant SBRT in various malignancies

71	(Holyoake et al., 2021; Kishi et al., 2020; Liu et al., 2022; Novikov et al., 2021) are currently
72	ongoing. In addition, preclinical evidence suggested that SBRT has immunomodulatory properties
73	by inducing cancer cells necrosis and releasing neoantigens to boost neoantigen-specific immune
74	response and upregulate the expression of PD-L1 on tumor cells (Deng et al., 2014; Han et al., 2022;
75	Park et al., 2015). Given these, it would be promising to combine SBRT with ICIs and chemotherapy
76	under the neoadjuvant setting.
77	Therefore, we conducted a prospective pilot study to determine the efficacy and safety of
78	neoadjuvant SBRT in combination with adebrelimab (SHR-1316), a potent selective PD-L1
79	inhibitor, plus nab-paclitaxel and carboplatin in patients with newly-diagnosed early or locally
80	advanced TNBC, to validate the feasibility of this novel regimen in neoadjuvant treatment of TNBC.
81	
82	Methods
83	Patients
84	Previously untreated patients aged between 18 and 75 years, with histologically confirmed invasive
85	triple-negative breast cancer (defined as negative estrogen receptor, progesterone receptor and
86	HER2 status by American Society of Clinical Oncology/College of American Pathologists
87	guidelines) and pathological tumor size ≥ 2.0 cm in MRI assessment, were eligible for enrollment.
88	Other inclusion criteria included Eastern Cooperative Oncology Group performance score of 0-1,
89	adequate marrow, hepatic, renal and cardiac function.
90	Key exclusion criteria included bilateral, inflammatory or occult breast cancer; active or a history
91	of autoimmune disease; use of glucocorticoids or other immunosuppressive therapy within 2 weeks

- 92 before the first study dose; a history of interstitial pneumonia; active tuberculosis; pregnancy,
- 93 lactation, and refusal to use contraception.
- 94

95 Study design and treatment

- 96 This single-arm, prospective study was approved by the Institutional Review Board of Shengjing 97 Hospital, China Medical University and performed in accordance with the Declaration of Helsinki 98 and Good Clinical Practice. Written informed consent was obtained from each patient. This study 99 was reported following the Strengthening the Reporting of Observational Studies in Epidemiology 100 (STROBE) reporting guidelines. All patients intravenously received 8 cycles of adebrelimab (20 mg/kg every 3 weeks). SBRT 101 102 (24Gy/3f) targeted to breast lesion started at the second cycle every other day, and 6 cycles of nab-103 paclitaxel (125 mg/m² on days 1 and 8) and carboplatin (area under the curve 6 mg/mL per min on day 1) was given every 3 weeks since the third cycle. 104 105 Patients who completed or discontinued the neoadjuvant treatment could recieve surgery. If 106 disease progressed during the neoadjuvant phase, the patient would either proceed to surgery or 107 receive alternative neoadjuvant therapy. Surgery was performed 3-5 weeks after the last dose of 108 neoadjuvant therapy. Recommended surgery and adjuvant therapy were administered as per local 109 guidelines or institutional standards.
- 110

111 Outcomes

112 The primary endpoint was pCR rate in the breast and axillary lymph nodes (ypT0/is ypN0).

113	Secondary endpoints included ORR before surgery (defined as the proportion of patients with
114	complete or partial response according to the Response Evaluation Criteria in Solid Tumors
115	[RECIST] version 1.1), the proportion of residual cancer burden (RCB) 0-I, and safety according to
116	the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
117	
118	Statistical analysis
119	Efficacy was assessed in the modified intention-to-treat population, which included patients who
120	had undergone radiotherapy. Safety was evaluated in all recruited patients who received at least one
121	dose of study drug. All statistical analyses were conducted using SAS 9.4 (North Carolina, USA).
122	Continuous data are presented as mean and standard deviation (SD), or mean and 95% confidence
123	interval (CI). Categorical data are expressed as frequency and percentage. The 95% CIs of
124	pathological complete response rate, proportion of patients with RCB 0-I, and ORR were estimated
125	using the Clopper-Pearson method.
126	
127	Results
128	Patient characteristics
129	Between December 2021 and January 2023, 13 patients were enrolled in the trial (Figure 1). The
130	baseline characteristics are shown in <i>Table 1</i> . The median age was 51 years (range 31-68) and the
131	median tumor size was 33mm (range, 22-72). Lymph node involvement was seen in 53.8% (7/13)
132	patients and 46.2% (6/13) patients had stage III breast cancer at baseline.

134 Outcomes

135	Among the 13 treated patients, 2 (15.4%) were excluded after the first dose of adebrelimab due to
136	protocol deviation and 1 (7.7%) discontinued after the second dose of adebrelimab due to adverse
137	event, thus only 10 (76.9%) who underwent neoadjuvant SBRT and surgery (the modified intention-
138	to-treat population) were available for efficacy evaluation (<i>Figure 1</i>). 9 of the ten efficacy-evaluable
139	patients (90%, 95% CI 55.5%-99.8%) achieved pCR in the breast and axillary lymph nodes, and the
140	rates of RCB 0-I was 100% (95% CI 67.9%-100.0%). The radiologic ORR was 100% (95% CI
141	67.9%-100.0%, <i>Table 2</i> and <i>Figure 2</i>) with 3 patients achieved complete radiographic response. 4
142	patients with positive lymph node at baseline had nodal downstaging to N0 after neoadjuvant
143	treatment.
144	

145 Safety

AEs were reported in all 13 patients (Table 3). The incidence of any grade AEs was 92.4%. The 146 147 grade 3 or higher treatment-related adverse events occurred in 53.9% of the patients, including 148 neutropenia (30.8%), anemia (7.7%), leukopenia (7.7%), thrombocytopenia (7.7%), creatine phosphokinase elevation (7.7%) and diarrhea (7.7%). Immune-related adverse events of any grade 149 150 occurred in 23.1% of the patients with 1 (7.7%) patient experienced serious adverse events due to 151 immune-mediated myositis. 2 patients required a dose reduction of carboplatin due to AEs but 152 ultimately complete the prescribed treatment. There were no therapy-related death and no radiation-153 related dermatitis and skin hyperpigmentation.

155 Discussion

156	This pioneering study reported the efficacy and safety of neoadjuvant SBRT in combination with
157	adebrelimab, nab-paclitaxel and carboplatin in TNBC patients. This new therapeutic regimen
158	achieved promising anti-tumor activity with pCR rate of 90%, and the RCB 0-I and ORR rate of
159	100%, respectively. More importantly, this combinatory therapeutic strategy was well tolerated in
160	this population.

For TNBC patients who are candidates for preoperative therapy, neoadjuvant chemotherapy 161 162 combined with ICIs has already achieved pCR rate of 58-64.8% in KEYNOTE-522(Schmid et al., 163 2020) and IMpassion031 study (Mittendorf et al., 2020). In our study, the addition of SBRT to adebrelimab and standard neoadjuvant chemotherapy achieved a significantly higher percentage of 164 165 pCR (90%). Since the dose of SBRT at 24Gy in 3 fractions (bioequivalent dose [BED] = 43.2Gy) 166 was lower than conventional preoperative radiotherapy dose (45-50Gy/23-25 fractions) (Ahmed et al., 2021), we thought that SBRT (24Gy/3f) alone could rarely achieve pCR. We speculated that the 167 SBRT (24Gy/3f) may exert synergy with immunochemotherapy, and not just local tumor 168 169 eradication effects.

170 Recently, SBRT has been preclinically identified as exerting immunomodulatory effects and 171 synergizing anticancer immune responses combined with ICIs (Deng et al., 2014; Park et al., 2015). 172 Pilones et al (Pilones et al., 2020) discovered that SBRT (two doses of 12 Gy) improved the 173 therapeutic effects of PD-1 in a triple-negative breast cancer murine model, and this effect was 174 enhanced by the addition of chemotherapy. TONIC trial demonstrated that SBRT (24Gy/3f) 175 combined with nivolumab can increase the proportion of patients free of progression at 24 weeks

176	than nivolumab alone (17% vs 8%) (Voorwerk et al., 2019). Another small sample research has
177	indicated that preoperative SBRT (19.5-31.5Gy/3f) with neoadjuvant chemotherapy may result in
178	fair pCR rates of 36%, with the maximum response (pCR 67%) was obtained at a dose of 25.5Gy/3f
179	(Bondiau et al., 2013), as well as no increase in the incidences of early or late-term adverse events
180	(AEs) (Piras et al., 2023; Takanen et al., 2022). Together, these studies suggested SBRT may have
181	strong immunomodulatory effects, rendering a synergistic antitumor effect with immunotherapy
182	and chemotherapy.

183 Another study exploring SBRT(24Gy/3f) in combination with pembrolizumab plus 184 chemotherapy in a neoadjuvant setting for TNBC patients also achieved a promising pCR rate of 74% (PEARL) (McArthur et al., 2022). Noteworthy, PEARL study chose taxane-based 185 186 chemotherapy in which 52% of patients received platinum, while our study used nab-paclitaxel and 187 carboplatin-based regimens. It is well-established that neoadjuvant chemotherapy containing platinum has shown an increase in pCR rates of approximately 15.1% in TNBC patients (Poggio et 188 al., 2018). Additionally, the IMpassion 130 (Emens et al., 2021) and IMpassion 131 (Miles et al., 189 190 2021) studies have suggested that nab-paclitaxel combined with ICIs may exhibit greater efficacy 191 than paclitaxel. Thus, it is hypothesized that the selection of a chemotherapy regimen may contribute 192 to the difference of pCR rates between the PEARL and our study (74% vs 90%). Consequently, it is imperative to determine the optimal neoadjuvant chemotherapy partners for ICIs in TNBC 193 194 population.

Adverse events observed in our study were generally consistent with the known safety profiles of neoadjuvant therapy for TNBC patients in KEYNOTE-522 (Schmid et al., 2020) and

197	IMpassion031 (Mittendorf et al., 2020) trials. The addition of SBRT did not increase any grades or
198	grade 3 or above AEs, which were 92.3% vs 99% and 53.8% vs 57-76.8%, respectively.
199	Furthermore, consistent with the customary toxic effects observed in lung cancers with adebrelimab
200	plus carboplatin-based chemotherapy regimen (Wang et al., 2022; Yan et al., 2023), the addition of
201	SBRT neither brought new AEs nor increased the incidences of grade 3 or higher or serious AEs in
202	our population.
203	Our study had several limitations including a non-comparative preliminary trial with relatively
204	small sample size, thereby impeding the comparison of our data with historical data due to
205	insufficient statistical power. Thus, further prospective randomized clinical trial required to validate
206	these outcomes is currently at the planning stage.
207	In conclusion, the addition of SBRT to adebrelimab and neoadjuvant platinum-containing therapy
208	showed the possibility of a convenient and feasible regimen for TNBC with promising efficacy and
209	acceptable toxicities. Neoadjuvant radiotherapy may enhance the response to immunochemotherapy
210	through activating tumor microenvironment. Further confirmation of these findings in large-scale
211	study is currently underway.
212	

213 Acknowledgments

- 214 Jiangsu Hengrui Pharmaceuticals Co., Ltd provided the study drug adebrelimab free of charge for
- 215 patients enrolled in the study. We thank the patients and their families involved in this study.

216

- 217 Additional information
- 218 **Conflict of interest**
- 219 Yan Xia and Huajun Li are the employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other
- 220 potential conflicts of interest were reported.

221

222 Funding

- 223 This research did not receive any specific grant from funding agencies in the public, commercial,
- 224 or not-for-profit sectors.

225

226 Authors' contributions

- 227 G. Chen, Data curation, methodology. X. Gu, Data curation, Methodology. X. Zhang, Methodology.
- 228 X. Yu, Methodology. Y. Zhang: Data curation, formal analysis, methodology. J. Xue, Methodology.
- 229 A. Li, Conceptualization, methodology. Y. Zhao, Methodology. G. He, Methodology. M. Tang,
- 230 Data curation. F. Xing, Methodology. J. Yin, Methodology. X. Bian, Methodology. Y. Han,
- 231 Methodology. S. Cao, Methodology. C. Liu, Formal analysis, methodology. X. Jiang, Writing-
- 232 original draft. K. Zhang, Methodology. Y. Xia, Formal analysis. H. Li, Formal analysis. N. Niu,
- 233 Validation, data curation, formal analysis, methodology, writing-review and editing. Caigang Liu,

- 234 Conceptualization, supervision, project administration, writing-review and editing.
- 235

236 Author ORCIDs

- 237 Caigang Liu https://orcid.org/0000-0003-2083-235X
- 238
- 239 Ethics approval and consent to participate
- 240 The study was approved by Institutional Review Board of Shengjing Hospital, China Medical
- 241 University and performed, according to the Declaration of Helsinki and Good Clinical Practice
- 242 guidelines. Written informed consent was obtained from each patient.
- 243

244 **Consent for publication**

- All authors have read and approved the final version of this manuscript.
- 246

247 Data availability statement

The raw clinical and imaging data are protected due to patient privacy laws. The datasets generated and/or analyzed during the current study are restricted from public access by related policy and law, but available from the corresponding author upon reasonable request for 10 years; de-identified clinical data and experimental data are available on request sharing, which will need the approval of the Institutional Ethical Committees. De-identified data will then be transferred to the inquiring investigator over secure file transfer.

255 References

- Ahmed, M., Jozsa, F., & Douek, M. (2021). A systematic review of neo-adjuvant radiotherapy in the
 treatment of breast cancer. *Ecancermedicalscience*, *15*, 1175.
 https://doi.org/10.3332/ecancer.2021.1175
- 259
- Atun, R., Jaffray, D. A., Barton, M. B., Bray, F., Baumann, M., Vikram, B., Hanna, T. P., Knaul, F. M.,
 Lievens, Y., Lui, T. Y., Milosevic, M., O'Sullivan, B., Rodin, D. L., Rosenblatt, E., Van Dyk, J.,
 Yap, M. L., Zubizarreta, E., & Gospodarowicz, M. (2015, Sep). Expanding global access to
 radiotherapy. *Lancet Oncol, 16*(10), 1153-1186. <u>https://doi.org/10.1016/S1470-</u>
 2045(15)00222-3
- 265

271

275

- Bondiau, P. Y., Courdi, A., Bahadoran, P., Chamorey, E., Queille-Roussel, C., Lallement, M., BirtwislePeyrottes, I., Chapellier, C., Pacquelet-Cheli, S., & Ferrero, J. M. (2013, Apr 1). Phase 1
 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant
 chemotherapy for breast cancer. *Int J Radiat Oncol Biol Phys*, *85*(5), 1193-1199.
 https://doi.org/10.1016/j.ijrobp.2012.10.034
- Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020, Jul 28). SBRT combined with PD-1/PD-L1
 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future
 challenges. *J Hematol Oncol, 13*(1), 105. <u>https://doi.org/10.1186/s13045-020-00940-z</u>
- 276 Citrin, D. E. (2017, Sep 14). Recent Developments in Radiotherapy. *N Engl J Med, 377*(11), 1065 277 1075. <u>https://doi.org/10.1056/NEJMra1608986</u>
- 278
 - 279 Costa, R., Shah, A. N., Santa-Maria, C. A., Cruz, M. R., Mahalingam, D., Carneiro, B. A., Chae, Y. K., 280 Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017, Feb). Targeting Epidermal Growth 281 Factor Receptor in triple negative breast cancer: New discoveries and practical insights for 111-119. 282 drug development. Cancer Treat Rev. *53*, 283 https://doi.org/10.1016/j.ctrv.2016.12.010
 - Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y. X. (2014, Feb).
 Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
 J Clin Invest, 124(2), 687-695. <u>https://doi.org/10.1172/JCI67313</u>
 - 288

284

289 Emens, L. A., Adams, S., Barrios, C. H., Dieras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A., 290 Winer, E. P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Patel, S., Chui, S. Y., & 291 Schmid, P. (2021, Aug). First-line atezolizumab plus nab-paclitaxel for unresectable, 292 locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall 293 survival analysis. Ann Oncol. *32*(8), 983-993. 294 https://doi.org/10.1016/j.annonc.2021.05.355 295

296 Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, 297 H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Hurvitz, 298 S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., Leitch, M., Lyons, J., 299 Mortimer, J., Patel, S. A., Pierce, L. J., Rosenberger, L. H., Rugo, H. S., Sitapati, A., Smith, K. 300 L., Smith, M. L., Soliman, H., Stringer-Reasor, E. M., Telli, M. L., Ward, J. H., Wisinski, K. B., 301 Young, J. S., Burns, J., & Kumar, R. (2022, Jun). Breast Cancer, Version 3.2022, NCCN 302 Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(6), 691-722. 303 https://doi.org/10.6004/jnccn.2022.0030

- Han, M. G., Wee, C. W., Kang, M. H., Kim, M. J., Jeon, S. H., & Kim, I. A. (2022, May 29). Combination
 of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine TripleNegative Breast Cancer Model. *Cancers (Basel), 14*(11).
 https://doi.org/10.3390/cancers14112692
- Holyoake, D. L. P., Robinson, M., Silva, M., Grose, D., McIntosh, D., Sebag-Montefiore, D.,
 Radhakrishna, G., Mukherjee, S., & Hawkins, M. A. (2021, Feb). SPARC, a phase-I trial of
 pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic
 cancer. *Radiother Oncol, 155*, 278-284. <u>https://doi.org/10.1016/j.radonc.2020.11.007</u>
- Keenan, T. E., & Tolaney, S. M. (2020, Apr). Role of Immunotherapy in Triple-Negative Breast
 Cancer. J Natl Compr Canc Netw, 18(4), 479-489.
 <u>https://doi.org/10.6004/jnccn.2020.7554</u>
- Kishi, N., Kanayama, N., Hirata, T., Ohira, S., Wada, K., Kawaguchi, Y., Konishi, K., Nagata, S.,
 Nakatsuka, S. I., Marubashi, S., Tomokuni, A., Wada, H., Kobayashi, S., Tomita, Y., &
 Teshima, T. (2020, Mar 5). Preoperative Stereotactic Body Radiotherapy to Portal Vein
 Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis. *Sci Rep, 10*(1), 4105. <u>https://doi.org/10.1038/s41598-020-60871-0</u>
- Liu, Y., Veale, C., Hablitz, D., Krontiras, H., Dalton, A., Meyers, K., Dobelbower, M., Lancaster, R.,
 Bredel, M., Parker, C., Keene, K., Thomas, E., & Boggs, D. (2022). Feasibility and Short Term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation
 Therapy Regimen in Early-Stage Breast Cancer Patients Receiving Partial Breast Irradiation.
 Front Oncol, 12, 901312. <u>https://doi.org/10.3389/fonc.2022.901312</u>
- Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V.,
 Badve, S., Demaria, S., Gray, R., Munzone, E., Lemonnier, J., Sotiriou, C., Piccart, M. J.,
 Kellokumpu-Lehtinen, P. L., Vingiani, A., Gray, K., Andre, F., Denkert, C., Salgado, R., &
 Michiels, S. (2019, Mar 1). Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled
 Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*, *37*(7), 559-569. <u>https://doi.org/10.1200/JCO.18.01010</u>
- 337

304

309

314

318

324

338 McArthur, H. L., Shiao, S., Karlan, S., Basho, R., Amersi, F., Burnison, M., Mirhadi, A., Chung, A., 339 Chung, C. T., Dang, C., Richardson, H., Giuliano, A. E., Kapoor, N., Larkin, B., Godinez, H., 340 Dunn, S. A., Khameneh, N. H., Knott, S., McAndrew, P., Mita, M., Park, D. J., Abaya, C., Chen, 341 J. H., Ly, A., Bossuyt, V., & Ho, A. (2022). Abstract PD10-01: The PEARL trial: Pre-operative 342 pembrolizumab with radiation therapy in early stage triple negative breast cancer. Cancer 343 Research, 82(4_Supplement), PD10-01-PD10-01. https://doi.org/10.1158/1538-344 7445.Sabcs21-pd10-01

345

353

361

- Miles, D., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen,
 D., Andrade, L., Semiglazov, V., Reinisch, M., Patel, S., Patre, M., Morales, L., Patel, S. L.,
 Kaul, M., Barata, T., O'Shaughnessy, J., & investigators, I. M. (2021, Aug). Primary results
 from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of
 first-line paclitaxel with or without atezolizumab for unresectable locally
 advanced/metastatic triple-negative breast cancer. *Ann Oncol, 32*(8), 994-1004.
 https://doi.org/10.1016/j.annonc.2021.05.801
- Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata,
 H., Telli, M. L., Ferrario, C., Punie, K., Penault-Llorca, F., Patel, S., Duc, A. N., Liste-Hermoso,
 M., Maiya, V., Molinero, L., Chui, S. Y., & Harbeck, N. (2020, Oct 10). Neoadjuvant
 atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based
 chemotherapy versus placebo and chemotherapy in patients with early-stage triplenegative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet, 396*(10257), 1090-1100. <u>https://doi.org/10.1016/S0140-6736(20)31953-X</u>
- Nicosia, L., Figlia, V., Ricottone, N., Cuccia, F., Mazzola, R., Giaj-Levra, N., Ricchetti, F., Rigo, M.,
 Jafari, F., Maria Magrini, S., Girlando, A., & Alongi, F. (2022, Aug). Stereotactic body
 radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer
 patients. *Clin Exp Metastasis, 39*(4), 581-588. <u>https://doi.org/10.1007/s10585-022-</u>
 <u>10167-6</u>
- Novikov, S. N., Gafton, G. I., Ebert, M. A., Fedosova, E. A., Melnik, J. S., Zinovev, G. V., Gafton, I. G.,
 Sinyachkin, M. S., & Kanaev, S. V. (2021, Aug). Preoperative stereotactic ablative body
 radiotherapy with postoperative conventional irradiation of soft tissue sarcomas: Protocol
 overview with a preliminary safety report. *Radiother Oncol, 161*, 126-131.
 https://doi.org/10.1016/j.radonc.2021.05.025
- 373
- Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K.
 M., Olivier, K. R., & Kwon, E. D. (2015, Jun). PD-1 Restrains Radiotherapy-Induced
 Abscopal Effect. *Cancer Immunol Res, 3*(6), 610-619. <u>https://doi.org/10.1158/2326-</u>
 <u>6066.CIR-14-0138</u>
- 378
- Pilones, K. A., Hensler, M., Daviaud, C., Kraynak, J., Fucikova, J., Galluzzi, L., Demaria, S., & Formenti,

S. C. (2020, Oct 20). Converging focal radiation and immunotherapy in a preclinical model

300	
381	of triple negative breast cancer: contribution of VISTA blockade. Oncoimmunology, 9(1),
382	1830524. https://doi.org/10.1080/2162402X.2020.1830524
383	
384	Piras, A., Sanfratello, A., Boldrini, L., D'Aviero, A., Pernice, G., Sortino, G., Valerio, M. R., Gennari, R.,
385	D'Angelo, I., Marazzi, F., Angileri, T., & Daidone, A. (2023). Stereotactic Radiotherapy in
386	Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review.
387	<i>Oncol Res Treat, 46</i> (3), 116-123. https://doi.org/10.1159/000528640
388	Check heat, heat, heat, 110 120. https://doi.org/10.1103/000020010
389	Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., &
390	Lambertini, M. (2018, Jul 1). Platinum-based neoadjuvant chemotherapy in triple-
390 391	
	negative breast cancer: a systematic review and meta-analysis. <i>Ann Oncol, 29</i> (7), 1497-
392	1508. <u>https://doi.org/10.1093/annonc/mdy127</u>
393	
394	Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kummel, S., Bergh, J., Denkert, C., Park, Y. H., Hui,
395	R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L.,
396	Karantza, V., Zhao, J., Aktan, G., Dent, R., O'Shaughnessy, J., & Investigators, K (2020,
397	Feb 27). Pembrolizumab for Early Triple-Negative Breast Cancer. <i>N Engl J Med, 382</i> (9),
398	810-821. https://doi.org/10.1056/NEJMoa1910549
399	
400	Takanen, S., Pinnaro, P., Farina, I., Sperati, F., Botti, C., Vici, P., Soriani, A., Marucci, L., & Sanguineti,
401	G. (2022). Stereotactic partial breast irradiation in primary breast cancer: A comprehensive
402	review of the current status and future directions. Front Oncol, 12, 953810.
403	https://doi.org/10.3389/fonc.2022.953810
404	
405	Viani, G. A., Gouveia, A. G., Louie, A. V., Korzeniowski, M., Pavoni, J. F., Hamamura, A. C., & Moraes,
406	F. Y. (2021, Nov). Stereotactic body radiotherapy to treat breast cancer oligometastases:
407	A systematic review with meta-analysis. <i>Radiother Oncol, 164</i> , 245-250.
408	https://doi.org/10.1016/j.radonc.2021.09.031
409	
410	Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof,
411	I., Kluin, R. J. C., Warren, S., Ong, S., Wiersma, T. G., Russell, N. S., Lalezari, F., Schouten, P.
412	C., Bakker, N. A. M., Ketelaars, S. L. C., Peters, D., Lange, C. A. H., van Werkhoven, E., van
413	Tinteren, H., Mandjes, I. A. M., Kemper, I., Onderwater, S., Chalabi, M., Wilgenhof, S.,
414	Haanen, J., Salgado, R., de Visser, K. E., Sonke, G. S., Wessels, L. F. A., Linn, S. C.,
415	Schumacher, T. N., Blank, C. U., & Kok, M. (2019, Jun). Immune induction strategies in
416	metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the
417	TONIC trial. <i>Nat Med, 25</i> (6), 920-928. https://doi.org/10.1038/s41591-019-0432-4
418	
419	Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., Yang, R., Yu,
420	G., Gong, Y., Zhao, J., Fan, Y., Liu, Q., Cao, L., Yao, Y., Liu, Y., Li, X., Wu, J., He, Z., Lu, K.,
421	Jiang, L., Hu, C., Zhao, W., Zhang, B., Shi, W., Zhang, X., Cheng, Y., & Group, CS. (2022,
	17

Jun). Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for
extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised,
double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol, 23*(6), 739-747.
https://doi.org/10.1016/S1470-2045(22)00224-8

- 426
- Yan, W., Zhong, W. Z., Liu, Y. H., Chen, Q., Xing, W., Zhang, Q., Liu, L., Ge, D., Chen, K., Yang, F., Lin,
 X., Song, L., Shi, W., & Wu, Y. L. (2023, Feb). Adebrelimab (SHR-1316) in Combination With
 Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III
 NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. *J Thorac Oncol, 18*(2), 194-203.
 https://doi.org/10.1016/j.jtho.2022.09.222
- 432
- 433
- 434

Table 1. Baseline characteristics

Characteristic	Patients (n=13)
Age (median, range)	51 (31-68)
Age Group, years	
≤ 50	6 (46.2%)
> 50	7 (53.8%)
Menopausal status	
Premenopausal	6 (46.2%)
Postmenopausal	7 (53.8%)
Tumor size	
T2	10 (76.9%)
Т3	3 (23.1%)
Lymph node status	
NO	6 (46.2%)
N1	2 (15.4%)
N2	5 (38.5%)
Clinical stage	
IIA	6 (46.2%)
IIB	1 (7.7%)
IIIA	6 (46.2%)
Tumor grade	
II	6 (46.2%)
III	5 (38.5%)
Unknown	2 (15.4%)
HER2 expression	
Negative	8 (61.5%)
1+	3 (23.1%)
2+, FISH-	2 (15.4%)

Variable	Patients (n=10)
Total pathological complete response	9 (90%)
Residual cancer burden score	
0	9 (90%)
Ι	1 (10%)
II	0
III	0
Radiological response	
Complete response	3 (30%)
Partial response	7 (70%)
Stable disease	0
Objective response rate	10 (100%)

Table 2. Pathological and clinical response

Table 3. Treatment-related adverse events

	Patients (n=13)		
	Grade 1 or 2	Grade 3	Grade 4
Total	5 (38.5%)	6 (46.2%)	1 (7.7%)
Anemia	8 (61.5%)	1 (7.7%)	0
Alopecia	9 (69.2%)	0	0
Neutropenia	4 (30.8%)	3 (23.1%)	1 (7.7%)
Hyponatremia	8 (61.5%)	0	0
Nausea	8 (61.5%)	0	0
Leukopenia	6 (46.2%)	1 (7.7%)	0
Lymphopenia	7 (53.8%)	0	0
Thrombocytopenia	5 (38.5%)	1 (7.7%)	0
Elevated alanine aminotransferase level	5 (38.5%)	0	0
Elevated aspartate aminotransferase level	5 (38.5%)	0	0
Thyroid stimulating hormone decreased	5 (38.5%)	0	0
Hyperuricemia	5 (38.5%)	0	0
Vomiting	5 (38.5%)	0	0
Fatigue	4 (30.8%)	0	0
γ-glutamyl transferase increased	3 (23.1%)	0	0
Creatinine increased	3 (23.1%)	0	0
Thyroid stimulating hormone increased	3 (23.1%)	0	0
Creatine phosphokinase elevation	1 (7.7%)	1 (7.7%)	0
Hyperthyroidism	2 (15.4%)	0	0
Free thyroid hormone decreased	2 (15.4%)	0	0
Hyperglycemia	2 (15.4%)	0	0
Hypokalemia	2 (15.4%)	0	0
Rash	2 (15.4%)	0	0
Peripheral neuropathy	2 (15.4%)	0	0
Diarrhea	0	1 (7.7%)	0
Immune mediated myositis	1 (7.7%)	0	0
Ventricular extrasystole	1 (7.7%)	0	0
Free thyroid hormone increased	1 (7.7%)	0	0
Hypothyroidism	1 (7.7%)	0	0
Troponin I elevated	1 (7.7%)	0	0
Proteinuria	1 (7.7%)	0	0
Constipation	1 (7.7%)	0	0

443 **FIGURE LEGENDS**

- 444 **Figure 1** Flowchart of the trial. SBRT, stereotactic body radiotherapy.
- 445 Figure 2 Swimming plot which demonstrate the pCR, RCB and radiological response profile of ten
- 446 modified intention-to-treat population who received radiotherapy and undergone surgery. Each
- 447 round dot or column indicates a patient. Colors indicate different clinical stage. ID, identity; pCR,
- 448 pathological complete response; RCB, residual cancer burden.



